Tech Company Financing Transactions

Elcelyx Therapeutics Funding Round

On 10/2/2015, Elcelyx Therapeutics raised $40 million in Series E investment from Sailing Capital, GSM Fund and Kleiner Perkins Caufield & Byers.

Transaction Overview

Company Name
Elcelyx Therapeutics
Announced On
10/2/2015
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series E
Investors

Sailing Capital (Lead Investor) (Liang Tsui)

GSM Fund (Richard Barry)

Kleiner Perkins Caufield & Byers (Brook Byers)

Morgenthaler Ventures (Ralph Christofferson)

Technology Partners (James Glasheen)

Proceeds Purpose
Proceeds from new investors Sailing Capital, certain investment funds for which Clough Capital Partners, L.P. serves as investment manager, and all existing investors, support the immediate initiation of a large Phase 2b, dose-ranging clinical trial to evaluate Metformin DR. An oral agent, Metformin DR is under development to fill the unmet needs of the 40 percent of type 2 diabetes patients who cannot currently use metformin due to contraindications or poor tolerability.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11995 El Camino Real 305
San Diego, CA 92130
USA
Phone
(858) 876-1814
Website
www.elcelyx.com
Email Address
[email protected]
Overview
40% of treated type 2 diabetes patients are not able to take metformin, the first-line and foundational therapy.
Profile
Elcelyx Therapeutics LinkedIn Company Profile
Social Media
Elcelyx Therapeutics Company Twitter Account
Company News
Elcelyx Therapeutics News
Facebook
Elcelyx Therapeutics on Facebook
YouTube
Elcelyx Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Alain Baron
  Alain Baron LinkedIn Profile  Alain Baron Twitter Account  Alain Baron News  Alain Baron on Facebook
Chief Financial Officer
Jay Sherwood
  Jay Sherwood LinkedIn Profile  Jay Sherwood Twitter Account  Jay Sherwood News  Jay Sherwood on Facebook
Chief Scientific Officer
Mark Fineman
  Mark Fineman LinkedIn Profile  Mark Fineman Twitter Account  Mark Fineman News  Mark Fineman on Facebook
VP - Regulatory Affairs
Thomas Bicsak
  Thomas Bicsak LinkedIn Profile  Thomas Bicsak Twitter Account  Thomas Bicsak News  Thomas Bicsak on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/2/2015: MoBeam venture capital transaction
Next: 10/2/2015: Neon Therapeutics venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to record every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.